Shares of Verastem Inc (NASDAQ:VSTM) fell 5.3% during trading on Friday . The stock traded as low as $0.88 and last traded at $0.90, 1,550,600 shares changed hands during trading. A decline of 18% from the average session volume of 1,890,377 shares. The stock had previously closed at $0.95.
Several brokerages have recently commented on VSTM. B. Riley set a $9.00 price target on shares of Verastem and gave the stock a “buy” rating in a research report on Friday, August 2nd. ValuEngine cut shares of Verastem from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. Verastem presently has a consensus rating of “Hold” and a consensus target price of $5.46.
The stock has a market cap of $70.29 million, a price-to-earnings ratio of -0.66 and a beta of 2.90. The company has a quick ratio of 5.46, a current ratio of 5.47 and a debt-to-equity ratio of 6.49. The firm’s 50 day moving average is $1.15 and its two-hundred day moving average is $1.37.
Verastem Company Profile (NASDAQ:VSTM)
Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.